1Department of Hepatobiliary Surgery, The First Affiliated Hospital,Jinan University, 2Dongpu Branch,The First Affiliated Hospital, Jinan University, 3Department of Vascular Intervention, The First Affiliated Hospital,Jinan University, 4Department of Nuclear Medicine, The First Affiliated Hospital,Jinan University, 5Department of Gastroenterology,The Second Affiliated Hospital of Nanchang University
Summary
This study illustrates the methodological potential of combining Yttrium-90 Trans-Arterial Radioembolization (Y-90 TARE) with an anti-PD-1 monoclonal antibody as an effective neoadjuvant strategy leading to hepatectomy in hepatocellular carcinoma (HCC) patients with a high initial recurrence risk. It emphasizes the safety, feasibility, and step-by-step procedural guidance of this approach.
